Expression of TLR3, 4, 7 and 9 in cutaneous malignant melanoma: Relationship with clinicopathological characteristics and prognosis

Archives of Dermatological Research

Volumn 305, Issue 1, 2013, Pages 59-67

  Eiro N ^a   Ovies, C ^a   Fernandez Garcia, B ^a   Alvarez Cuesta C C ^b   Gonzalez L ^a   Gonzalez L O ^a   Vizoso, F J ^a  

^a HOSPITAL DE JOVE   (Spain)

^b HOSPITAL DE CABUEÑES   (Spain)

Author keywords

Melanoma; Prognosis; Toll like receptors

Indexed keywords

TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MELANOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECURRENCE FREE SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; CHI-SQUARE DISTRIBUTION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MELANOMA; MIDDLE AGED; SKIN NEOPLASMS; TIME FACTORS; TOLL-LIKE RECEPTOR 3; TOLL-LIKE RECEPTOR 4; TOLL-LIKE RECEPTOR 7; TOLL-LIKE RECEPTOR 8; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION; YOUNG ADULT;

EID: 84872332945     PISSN: 03403696     EISSN: 1432069X     Source Type: Journal    
DOI: 10.1007/s00403-012-1300-y     Document Type: Article

References (44)

1. Akira S, Takeda K (2004) Toll-like receptor signalling. Nat Rev Immunol 4(7):499-511. doi: 10.1038/nri1391
2. Allhorn S, Boing C, Koch AA, Kimmig R, Gashaw I (2008) TLR3 and TLR4 expression in healthy and diseased human endometrium. Reprod Biol Endocrinol 6:40. doi: 10.1186/1477-7827-6-40
3. Armstrong BK, Kricker A (1994) Cutaneous melanoma. Cancer Surv 19-20:219-240
4. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit DG, Ding S, Eggermont AM, Flaherty KT, Gimotty PA, Kirkwood JM, McMasters KM, Mihm MC Jr, Morton DL, Ross MI, Sober AJ, Sondak VK (2009) Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27(36):6199-6206. doi: 10.1200/JCO.2009.23.4799
5. Balkwill F (2002) Tumor necrosis factor or tumor promoting factor? Cytokine Growth Factor Rev 13(2):135-141. doi: S135961010100020X
6. Bhattacharya D, Yusuf N (2012) Expression of toll-like receptors on breast tumors: taking a toll on tumor microenvironment. Int J Breast Cancer 2012:716564. doi: 10.1155/2012/716564
7. Boring CC, Squires TS, Tong T (1993) Cancer statistics, 1993. CA Cancer J Clin 43(1):7-26
8. Breslow A, Macht SD (1978) Evaluation of prognosis in stage I cutaneous melanoma. Plast Reconstr Surg 61(3):342-346
9. Brightling CE, Ammit AJ, Kaur D, Black JL, Wardlaw AJ, Hughes JM, Bradding P (2005) The CXCL10/CXCR3 axis mediates human lung mast cell migration to asthmatic airway smooth muscle. Am J Respir Crit Care Med 171(10):1103-1108. doi: 10.1164/rccm.200409-1220OC
10. Cammarota R, Bertolini V, Pennesi G, Bucci EO, Gottardi O, Garlanda C, Laghi L, Barberis MC, Sessa F, Noonan DM, Albini A (2010) The tumor microenvironment of colorectal cancer: stromal TLR-4 expression as a potential prognostic marker. J Transl Med 8:112. doi: 10.1186/1479-5876-8-112
11. Cipponi A, Wieers G, van Baren N, Coulie PG (2011) Tumor-infiltrating lymphocytes: apparently good for melanoma patients. But why? Cancer Immunol Immunother 60(8):1153-1160. doi: 10.1007/s00262-011-1026-2
12. Cochran AJ (1997) Prediction of outcome for patients with cutaneous melanoma. Pigment Cell Res 10(3):162-167
13. de Visser KE, Coussens LM (2005) The interplay between innate and adaptive immunity regulates cancer development. Cancer Immunol Immunother 54(11):1143-1152. doi: 10.1007/s00262-005-0702-5
14. Ermertcan AT, Ozturk F, Gunduz K (2011) Toll-like receptors and skin. J Eur Acad Dermatol Venereol 25(9):997-1006. doi: 10.1111/j.1468-3083.2011.04049.x
15. Fang L, Lonsdorf AS, Hwang ST (2008) Immunotherapy for advanced melanoma. J Invest Dermatol 128(11):2596-2605. doi: 10.1038/jid.2008.101
16. Fukata M, Chen A, Vamadevan AS, Cohen J, Breglio K, Krishnareddy S, Hsu D, Xu R, Harpaz N, Dannenberg AJ, Subbaramaiah K, Cooper HS, Itzkowitz SH, Abreu MT (2007) Toll-like receptor-4 promotes the development of colitis-associated colorectal tumors. Gastroenterology 133(6):1869-1881. doi: 10.1053/j.gastro. 2007.09.008
17. Gonzalez-Reyes S, Fernandez JM, Gonzalez LO, Aguirre A, Suarez A, Gonzalez JM, Escaff S, Vizoso FJ (2011) Study of TLR3, TLR4, and TLR9 in prostate carcinomas and their association with biochemical recurrence. Cancer Immunol Immunother 60(2):217-226. doi: 10.1007/s00262-010-0931-0
18. Gonzalez-Reyes S, Marin L, Gonzalez L, Gonzalez LO, del Casar JM, Lamelas ML, Gonzalez-Quintana JM, Vizoso FJ (2010) Study of TLR3, TLR4 and TLR9 in breast carcinomas and their association with metastasis. BMC Cancer 10:665. doi: 10.1186/1471-2407-10-665
19. Goto Y, Arigami T, Kitago M, Nguyen SL, Narita N, Ferrone S, Morton DL, Irie RF, Hoon DS (2008) Activation of Toll-like receptors 2, 3, and 4 on human melanoma cells induces inflammatory factors. Mol Cancer Ther 7(11):3642-3653. doi: 10.1158/1535-7163.MCT-08-0582
20. Huang B, Zhao J, Unkeless JC, Feng ZH, Xiong H (2008) TLR signaling by tumor and immune cells: a double-edged sword. Oncogene 27(2):218-224. doi: 10.1038/sj.onc.1210904
21. Jin SH, Kang HY (2010) Activation of toll-like receptors 1, 2, 4, 5, and 7 on human melanocytes modulate pigmentation. Ann Dermatol 22(4):486-489. doi: 10.5021/ad.2010.22.4.486
22. Kaiser WJ, Kaufman JL, Offermann MK (2004) IFN-alpha sensitizes human umbilical vein endothelial cells to apoptosis induced by double-stranded RNA. J Immunol 172(3):1699-1710
23. Kang HY, Park TJ, Jin SH (2009) Imiquimod, a Toll-like receptor 7 agonist, inhibits melanogenesis and proliferation of human melanocytes. J Invest Dermatol 129(1):243-246. doi: 10.1038/jid.2008.184
24. Massi D, Borgognoni L, Franchi A, Martini L, Reali UM, Santucci M (2000) Thick cutaneous malignant melanoma: a reappraisal of prognostic factors. Melanoma Res 10(2):153-164
25. Merrill RM, Feuer EJ (1996) Risk-adjusted cancer-incidence rates (United States). Cancer Causes Control 7(5):544-552
26. Meyer T, Stockfleth E, Christophers E (2007) Immune response profiles in human skin. Br J Dermatol 157(Suppl 2):1-7. doi: 10.1111/j.1365-2133.2007.08264. x
27. Mittal D, Saccheri F, Venereau E, Pusterla T, Bianchi ME, Rescigno M (2010) TLR4-mediated skin carcinogenesis is dependent on immune and radioresistant cells. EMBO J 29(13):2242-2252. doi: 10.1038/emboj.2010.94
28. Miyake K (2007) Innate immune sensing of pathogens and danger signals by cell surface Toll-like receptors. Semin Immunol 19:8
29. Morikawa T, Sugiyama A, Kume H, Ota S, Kashima T, Tomita K, Kitamura T, Kodama T, Fukayama M, Aburatani H (2007) Identification of Toll-like receptor 3 as a potential therapeutic target in clear cell renal cell carcinoma. Clin Cancer Res 13(19):5703-5709. doi: 10.1158/1078-0432.CCR-07-0603
30. Moynagh PN (2005) TLR signalling and activation of IRFs: revisiting old friends from the NF-kappaB pathway. Trends Immunol 26(9):469-476. doi: 10.1016/j.it.2005.06.009
31. Nikolova PN, Pawelec GP, Mihailova SM, Ivanova MI, Myhailova AP, Baltadjieva DN, Marinova DI, Ivanova SS, Naumova EJ (2007) Association of cytokine gene polymorphisms with malignant melanoma in Caucasian population. Cancer Immunol Immunother 56(3):371-379. doi: 10.1007/s00262-006-0193-z
32. O'Neill LA, Bryant CE, Doyle SL (2009) Therapeutic targeting of Toll-like receptors for infectious and inflammatory diseases and cancer. Pharmacol Rev 61(2):177-197. doi: 10.1124/pr.109.001073
33. Parker RL, Huntsman DG, Lesack DW, Cupples JB, Grant DR, Akbari M, Gilks CB (2002) Assessment of interlaboratory variation in the immunohistochemical determination of estrogen receptor status using a breast cancer tissue microarray. Am J Clin Pathol 117(5):723-728. doi: 10.1309/PEF8-GL6F-YWMC-AG56
34. Pollard JW (2004) Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 4(1):71-78. doi: 10.1038/nrc1256
35. Raman D, Baugher PJ, Thu YM, Richmond A (2007) Role of chemokines in tumor growth. Cancer Lett 256(2):137-165. doi: 10.1016/j.canlet.2007.05.013
36. Saint-Jean M, Knol AC, Nguyen JM, Khammari A, Dreno B (2011) TLR expression in human melanoma cells. Eur J Dermatol 21(6):899-905. doi: 10.1684/ejd.2011.1526
37. Salaun B, Coste I, Rissoan MC, Lebecque SJ, Renno T (2006) TLR3 can directly trigger apoptosis in human cancer cells. J Immunol 176(8):4894-4901. doi: 176/8/4894
38. Salaun B, Lebecque S, Matikainen S, Rimoldi D, Romero P (2007) Toll-like receptor 3 expressed by melanoma cells as a target for therapy? Clin Cancer Res 13(15 Pt 1):4565-4574. doi: 10.1158/1078-0432.CCR-07-0274
39. Scarlett UK, Cubillos-Ruiz JR, Nesbeth YC, Martinez DG, Engle X, Gewirtz AT, Ahonen CL, Conejo-Garcia JR (2009) In situ stimulation of CD40 and Toll-like receptor 3 transforms ovarian cancer-infiltrating dendritic cells from immunosuppressive to immunostimulatory cells. Cancer Res 69(18):7329-7337. doi: 10.1158/0008-5472.CAN-09-0835
40. Seki E, Brenner DA (2008) Toll-like receptors and adaptor molecules in liver disease: update. Hepatology 48(1):322-335. doi: 10.1002/hep.22306
41. Shojaei H, Oberg HH, Juricke M, Marischen L, Kunz M, Mundhenke C, Gieseler F, Kabelitz D, Wesch D (2009) Toll-like receptors 3 and 7 agonists enhance tumor cell lysis by human gammadelta T cells. Cancer Res 69(22):8710-8717. doi: 10.1158/0008-5472.CAN-09-1602
42. Steinbrink K, Graulich E, Kubsch S, Knop J, Enk AH (2002) CD4(+) and CD8(+) anergic T cells induced by interleukin-10-treated human dendritic cells display antigen-specific suppressor activity. Blood 99(7):2468-2476
43. Swerlick RA, Chen S (1997) The melanoma epidemic: more apparent than real? Mayo Clin Proc 72(6):559-564
44. Valins W, Amini S, Berman B (2010) The expression of Toll-like receptors in dermatological diseases and the therapeutic effect of current and newer topical Toll-like receptor modulators. J Clin Aesthet Dermatol 3(9):20-29